Retifanlimab-dlwr: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 May 2024

  • curprev 20:3620:36, 20 May 2024‎ Rithish Nimmagadda talk contribs‎ 8,754 bytes −296‎ No edit summary
  • curprev 20:3320:33, 20 May 2024‎ Rithish Nimmagadda talk contribs‎ 9,050 bytes +86‎ No edit summary
  • curprev 20:3120:31, 20 May 2024‎ Rithish Nimmagadda talk contribs‎ 8,964 bytes +8,964‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=retifanlimab-dlwr |aOrAn=an |indicationType=treatment |indication=adults with metastatic or recurrent locally advanced Merkel cell carcinoma . Indication approved under accelerated approval based on tumor response rate and duration of response; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. |adverseReactions=Adverse effects (≥10%): fatigue..."
Retrieved from "https://www.wikidoc.org/index.php/Retifanlimab-dlwr"